Drug intelligence / Profile preview

belladonna + opium

Development stage: Phase 4
Lead developer: Padagis
Modality: Small Molecules
Administration: Rectal

Overview

Belladonna + opium is a combination medication available as a rectal suppository used to treat moderate to severe pain caused by ureteral spasms. It contains two active components: belladonna extract (containing atropine and scopolamine) which acts as an antispasmodic by relaxing the muscles in the ureter and bladder, and powdered opium (primarily containing morphine) which functions as a narcotic analgesic by affecting pain receptors in the brain. This medication is typically prescribed when other pain medications have not worked or cannot be tolerated.

Brand names: B&O Suppositories
Other names: Belladonna and Opium

Targets

mAChR (Muscarinic acetylcholine receptors)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on belladonna + opium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on belladonna + opium.

Explore the full profile